News

European Medicines Verification Organisation (EMVO) would like to highlight once again the consequences following Product Withdrawal and Batch recall and remind you that these are irreversible actions.

On May 12, at the European Medicines Verification Organisation’s (EMVO) General Assembly meeting, the NMVO Observers within EMVO’s Board for 2023 from the National Medicines Verification Organizations (NMVOs) were approved. As one of the observers representing the group of small-scale countries, will be the Latvian Medicines Verification Organisation (LZVO) and its Chairwoman of the Board Inese Erdmane.

The Latvian Medicines Verification Organisation (LZVO) in the fifth issue of the Newsletter (April 2023) looks back at the celebration of the fourth anniversary of the medicine verification system and looks at the current affairs of the first quarter of 2023.

The European Medicines Verification Organisation (EMVO) has launched a newsletter, which looks back on the past four years of the verification system’s operation, informs about the launch of the European Alert Management System (EAMS) and provides an opportunity to look into the first European Medicines Verification System’s (EMVS) forum, which was also attended by the Latvian Medicines Verification Organisation (LZVO) representatives Inese Erdmane and Andra Pučko.

The Latvian Medicines Verification Organization (LZVO) in the fourth issue of the Newsletter (January 2023) looks back at the year 2022 – the performance indicators of the LZVS in the 4th quarter of 2022 and the year as whole and highlights the current events of 2023.

Summarizing what was done in 2022 and outlining the plans for 2023, the European Medicines Verification Organisation (EMVO) in cooperation with the National Medicines Verification Organisations has published the EMVS Community Newsletter – 2022 Holiday Bulletin edition. In this bulletin, Inese Erdmane, Chairwoman of the Board at the Latvian Medicines Verification Organisation (LZVO), also talks about this year's achievements.